Novartis/Sandoz 1st to reveal biosimilars application at FDA
This article was originally published in Scrip
Executive Summary
It was inevitable some company would be the first with a biosimilar application before the FDA under the approval pathway created by Congress in 2010 as part of the Affordable Care Act (ACA), and now Novartis subsidiary Sandoz may just be that firm.